Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) — Cash Flow-to-Debt Ratio
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has a Cash Flow-to-Debt Ratio of -0.06x as of September 2025, meaning its operating cash flow of CN¥-19.96 Million could theoretically repay 0% of its total liabilities (CN¥335.43 Million) in one year. Explore Hangzhou TianMuShan Pharmaceutical Enter (600671) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd across 28 annual periods. Also explore 600671 total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1998–2025)
Year-by-year debt coverage analysis for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd. For market capitalisation and broader financial context, see 600671 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.03x | CN¥11.79 Million | CN¥348.04 Million | ▲ +132.9% |
| 2024 | -0.10x | CN¥-36.67 Million | CN¥356.44 Million | ▼ -46.2% |
| 2023 | -0.07x | CN¥-20.43 Million | CN¥290.34 Million | ▼ -7.3% |
| 2022 | -0.07x | CN¥-19.37 Million | CN¥295.36 Million | ▲ +16.1% |
| 2021 | -0.08x | CN¥-26.42 Million | CN¥338.09 Million | ▼ -225.0% |
| 2020 | -0.02x | CN¥-8.40 Million | CN¥349.18 Million | ▼ -105.9% |
| 2019 | 0.41x | CN¥161.13 Million | CN¥393.60 Million | ▲ +131.0% |
| 2018 | 0.18x | CN¥70.71 Million | CN¥398.99 Million | ▲ +156.0% |
| 2017 | 0.07x | CN¥24.52 Million | CN¥354.18 Million | ▲ +934.1% |
| 2016 | 0.01x | CN¥1.61 Million | CN¥240.01 Million | ▲ +199.4% |
| 2015 | -0.01x | CN¥-1.47 Million | CN¥217.63 Million | ▼ -306.5% |
| 2014 | 0.00x | CN¥653.79K | CN¥200.40 Million | ▼ -93.9% |
| 2013 | 0.05x | CN¥12.37 Million | CN¥230.01 Million | ▲ +155.1% |
| 2012 | -0.10x | CN¥-19.82 Million | CN¥203.17 Million | ▼ -163.0% |
| 2011 | -0.04x | CN¥-6.49 Million | CN¥175.00 Million | ▲ +51.2% |
| 2010 | -0.08x | CN¥-12.60 Million | CN¥165.66 Million | ▼ -240.9% |
| 2009 | 0.05x | CN¥7.58 Million | CN¥140.53 Million | ▼ -67.2% |
| 2008 | 0.16x | CN¥21.19 Million | CN¥128.78 Million | ▼ -54.6% |
| 2007 | 0.36x | CN¥47.53 Million | CN¥131.16 Million | ▼ -24.1% |
| 2006 | 0.48x | CN¥55.39 Million | CN¥116.04 Million | ▲ +650.2% |
| 2005 | 0.06x | CN¥8.48 Million | CN¥133.32 Million | ▲ +395.6% |
| 2004 | 0.01x | CN¥1.35 Million | CN¥105.49 Million | ▲ +103.2% |
| 2003 | -0.40x | CN¥-41.13 Million | CN¥103.88 Million | ▼ -318.6% |
| 2002 | 0.18x | CN¥21.80 Million | CN¥120.32 Million | ▲ +170.6% |
| 2001 | 0.07x | CN¥10.52 Million | CN¥157.11 Million | ▲ +207.0% |
| 2000 | -0.06x | CN¥-9.67 Million | CN¥154.60 Million | ▼ -112.2% |
| 1999 | 0.51x | CN¥49.09 Million | CN¥95.68 Million | ▲ +1800.8% |
| 1998 | 0.03x | CN¥2.36 Million | CN¥87.30 Million | — |